Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Felypressin→

Felypressin PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
56-59-7
Molecular formula
C46H65N13O11S2
Molecular weight
1040.2 g/mol
Drug class
Synthetic vasopressin analoguelocal vasoconstrictor used with selected dental local anaesthetic products
Mechanism of action
Acts on vasopressin V1 receptors in vascular smooth muscle to produce vasoconstriction, reducing local blood flow and prolonging the effect of the accompanying local anaesthetic. It has less direct cardiac stimulation than adrenergic vasoconstrictors.

Sources: NLM MeSH — Felypressin · PubMed review — Vasoconstrictors in local anaesthesia · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Synthetic vasopressin analogue; local vasoconstrictor used with selected dental local anaesthetic products

Mechanism of action

Acts on vasopressin V1 receptors in vascular smooth muscle to produce vasoconstriction, reducing local blood flow and prolonging the effect of the accompanying local anaesthetic. It has less direct cardiac stimulation than adrenergic vasoconstrictors.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Felypressin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Felypressin Permitted Daily Exposure (PDE) report (the Felypressin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Felypressin Occupational Exposure Limit (OEL) report (the Felypressin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.